NEWOMICS INC. — Department of Health and Human Services SBIR Phase II: NIA

Description

Project Summary Abstract Alzheimerandapos s diseaseADis a devastating neurodegenerative disease that affects more thanmillion peopleincludingmillion Americansworldwideand this number is expected to reach more thanmillion by the yearRecent disappointing results from a large number of clinical trials for AD treatment further aggravate the problemOne major challenge is there is currently no blood based biomarker for early diagnosis or target therapy of ADThe field is calling for transformative technologies and approachesIn response to PASNewomics Incproposes this SBIR Phase II project to complete development of its productAD MS chips and multiomics assays enabled by these microfluidic chipsfor biofluids based diagnosis of ADThe Phase II project is built upon the promising results generated from our Phase I projectIn Phase Iwe have developed the integrated silicon microfluidic chips as a high throughput and multiplex platform for LC MS based multiomics assaysWe have performed preliminary multiomics experiments on clinical samples using our unique platformFurthermorewe have implemented statistical and bioinformatics methods to discover new biomarker panels and pathways and networks for early diagnosis of ADIn Phase IIwe will optimize and validate our platform and multiomics assays with large cohorts of both retrospective and prospective clinical samplesOnce developedNewomicsandaposintegrated platforms and solutions will enable rapidlow costreproduciblehighly specific and sensitive multiplex measurements of human peripheral blood and CSF samplesand contribute to early diagnosis and target therapy of AD Project Narrative Cutting edge technologies enable breakthroughs in biomedicineInnovative and integrated silicon microfluidic chips will accelerate the discovery and validation of biomarkersand improve the sensitivity and specificity of minimally invasive diagnosis and target therapy of Alzheimerandapos s disease